Literature DB >> 9009335

Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.

T Belay1, R Cherniak, T R Kozel, A Casadevall.   

Abstract

Cryptococcus neoformans glucuronoxylomannans (GXM) are capsular polysaccharides important for virulence in cryptococcosis. This study used dot enzyme assays (DEA) and enzyme-linked immunosorbent assays (ELISA) to determine the reactivity patterns of 21 murine monoclonal antibodies (MAbs) with structurally defined GXMs from five serotypes. The MAbs were categorized into eight groups on the basis of DEA and five groups on the basis of ELISA. MAbs 302, 339, and 439 were studied extensively for their binding to various native and chemically modified GXMs. Quantitative variation in the inhibitory effects of GXMs on the binding of MAbs 302, 339, and 439 were observed by competitive ELISA. O-Deacetylation of serotype A, B, and D GXM resulted in the complete loss of their inhibitory properties. Carboxyl group reduction of GXMs from serotypes A and D resulted in a significant decrease of inhibitory activity for MAb. Xylomannans and methyl glycosides exhibited no detectable inhibitory activity on MAb binding to GXM. The results indicate (i) the existence of five to eight MAb-defined distinct epitopes in C. neoformans GXM that can elicit antibody responses, (ii) MAb detection of antigenic variation within GXMs assigned to a particular serotype, (iii) good correspondence between the patterns of MAb reactivities and polyclonal rabbit factor sera, (iv) good agreement between MAb molecular structure and serotype reactivity, and (v) a dependence of the serotype reactivity profile for a given MAb on the technique used to measure binding.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9009335      PMCID: PMC176118          DOI: 10.1128/iai.65.2.718-728.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Type-specific polysaccharides of Cryptococcus neoformans. n.m.r.-spectral study of a glucuronomannan chemically derived from a Tremella mesenterica exopolysaccharide.

Authors:  R Cherniak; R G Jones; M E Slodki
Journal:  Carbohydr Res       Date:  1988-11-01       Impact factor: 2.104

2.  Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.

Authors:  T F Eckert; T R Kozel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

3.  Enhanced binding of capsular polysaccharides of Cryptococcus neoformans to polystyrene microtitration plates for enzyme-linked immunosorbent assay.

Authors:  R Cherniak; M M Cheeseman; G H Reyes; E Reiss; F Todaro
Journal:  Diagn Clin Immunol       Date:  1988

4.  Cryptococcosis in the acquired immunodeficiency syndrome.

Authors:  J A Kovacs; A A Kovacs; M Polis; W C Wright; V J Gill; C U Tuazon; E P Gelmann; H C Lane; R Longfield; G Overturf
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

5.  Cryptococcosis in a cancer hospital: clinical and pathological correlates in forty-six patients.

Authors:  M H Kaplan; P P Rosen; D Armstrong
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

6.  Cryptococcus neoformans. 3. Inhibition of phagocytosis.

Authors:  G S Bulmer; M D Sans
Journal:  J Bacteriol       Date:  1968-01       Impact factor: 3.490

7.  Chemical characterization of capsular polysaccharide from Cryptococcus neoformans serotype A-D.

Authors:  R Ikeda; A Nishikawa; T Shinoda; Y Fukazawa
Journal:  Microbiol Immunol       Date:  1985       Impact factor: 1.955

8.  Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates.

Authors:  R Ikeda; T Shinoda; Y Fukazawa; L Kaufman
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

9.  Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.

Authors:  R A Fromtling; H J Shadomy; E S Jacobson
Journal:  Mycopathologia       Date:  1982-07-23       Impact factor: 2.574

Review 10.  Capsular polysaccharides of Cryptococcus neoformans.

Authors:  A K Bhattacharjee; J E Bennett; C P Glaudemans
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct
View more
  25 in total

1.  Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Mol Microbiol       Date:  2009-09-02       Impact factor: 3.501

2.  Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.

Authors:  G Nussbaum; S Anandasabapathy; J Mukherjee; M Fan; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

4.  Cas3p belongs to a seven-member family of capsule structure designer proteins.

Authors:  Frédérique Moyrand; Yun C Chang; Uwe Himmelreich; Kyung J Kwon-Chung; Guilhem Janbon
Journal:  Eukaryot Cell       Date:  2004-12

5.  Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.

Authors:  Raymond M Duro; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

6.  Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans.

Authors:  Oliver W Liu; Cheryl D Chun; Eric D Chow; Changbin Chen; Hiten D Madhani; Suzanne M Noble
Journal:  Cell       Date:  2008-10-03       Impact factor: 41.582

7.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Ctr2 links copper homeostasis to polysaccharide capsule formation and phagocytosis inhibition in the human fungal pathogen Cryptococcus neoformans.

Authors:  Cheryl D Chun; Hiten D Madhani
Journal:  PLoS One       Date:  2010-09-02       Impact factor: 3.240

Review 9.  How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans.

Authors:  Tamara Lea Doering
Journal:  Annu Rev Microbiol       Date:  2009       Impact factor: 15.500

10.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.